Appalanaidu Sasapu1*, Muthu K Veeraputhiran1, Pooja Motwani1, Mary Burgess2, Atul Kothari2, Juan Carlos Rico2 and Yogesh Jethava1
1Division of Hematology, University of Arkansas for Medical Sciences, USA
2Division of Infectious Diseases, University of Arkansas for Medical Sciences, USA
Acute Graft versus Host Disease (aGvHD) is a serious complication after allogeneic Hematopoietic Stem Cell Transplant (allo-SCT). Haploidentical-SCT (haplo-SCT) is increasingly utilized as it offers reliable and expeditious source for stem cells. However the incidence of aGvHD and high non-relapse mortality after haplo-SCT is a major concern. Glucocorticoids are still the gold standard therapy for aGvHD, but up to 50% of patients with acute gastro-intestinal and liver aGvHD are steroid refractory and the outcome of such steroid refractory patients is universally poor. There are no standard of care guidelines for steroid-refractory aGVHD and various modalities have been tried. We report a patient with B-ALL who developed steroid-refractory grade IV aGvHD of gut and liver after haplo-SCT, which was successfully treated with alemtuzumab. To our knowledge, this is first case report of successful use of alemtuzumab for treatment of steroid refractory aGvHD in haplo-SCT.
Haploidentical-stem cell transplant; GVHD; Alemtuzumab
Sasapu A, Veeraputhiran MK, Motwani P, Burgess M, Kothari A, Rico JC, et al. Complete Resolution of SteroidRefractory Acute Graft-Versus-Host Disease using Alemtuzumab after Haplo-Identical Transplant. Am J Leuk Res. 2018;2(1):1011.